{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:16:40Z","timestamp":1782479800410,"version":"3.54.5"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to validate a 15-item screening questionnaire for the early detection of coexisting type 2 (T2) inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps (CRSwNP), among others.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The questionnaire, designed through expert consensus by a scientific committee, underwent Delphi methodology for validation. A multidisciplinary panel of 19 clinicians from different specialties reviewed the questionnaire for clinical relevance, while 39 patients from different regions of Spain evaluated its comprehensibility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The clinician panel reached a consensus on the relevance of 13 out of 15 items in the first round and agreed that a single positive response was sufficient to justify referral to the appropriate specialist. Two items were modified and validated in the second round. The patient panel unanimously agreed on the comprehensibility of the questionnaire in the first round. Linguistic variations were also ranked to ensure clarity across regions, further enhancing the validation of the tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This validated questionnaire offers a practical tool for early detection of T2 inflammatory diseases. Its simplicity and comprehensibility, confirmed by clinicians and patients, make it suitable for use in various healthcare settings, supporting timely specialist referrals and improved patient care. Future studies will evaluate its effectiveness in real-world clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1543504","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T05:13:14Z","timestamp":1743657194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of a Delphi consensus-based questionnaire for the multidisciplinary management of type 2 inflammation-related diseases"],"prefix":"10.3389","volume":"6","author":[{"given":"Francisco Javier","family":"Ortiz de Frutos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s40495-017-0114-1","article-title":"Type 2 cytokine responses: regulating immunity to helminth parasites and allergic inflammation","volume":"3","author":"Henry","year":"2017","journal-title":"Curr Pharmacol Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.2147\/jir.S311640","article-title":"Insights into the implications of coexisting type 2 inflammatory diseases","volume":"14","author":"McCormick","year":"2021","journal-title":"J Inflamm Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/cea.14029","article-title":"Type 2 immunity-driven diseases: towards a multidisciplinary approach","volume":"51","author":"Hassoun","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"889221","DOI":"10.3389\/falgy.2022.889221","article-title":"White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by euforea","volume":"3","author":"De Prins","year":"2022","journal-title":"Front Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1427279","DOI":"10.3389\/falgy.2024.1427279","article-title":"Multidisciplinary management of type 2 inflammation diseases using a screening tool","volume":"5","author":"Palomares","year":"2024","journal-title":"Front Allergy"},{"key":"B6","volume-title":"The Rand\/Ucla Appropriateness Method User\u2019s Manual.","author":"Fitch","year":"2001"},{"key":"B7","doi-asserted-by":"publisher","first-page":"190054","DOI":"10.1183\/16000617.0054-2019","article-title":"Severe T2-high asthma in the biologics era: european experts\u2019 opinion","volume":"28","author":"Pavord","year":"2019","journal-title":"Eur Respir Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jaip.2021.11.016","article-title":"The role of comorbidities in difficult-to-control asthma in adults and children","volume":"10","author":"Gaffin","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1365-2648.2003.02537.x","article-title":"The delphi technique: myths and realities","volume":"41","author":"Powell","year":"2003","journal-title":"J Adv Nurs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12873-022-00617-5","article-title":"Establishing the content validity of a new emergency department patient-reported experience measure (ed Prem): a Delphi study","volume":"22","author":"Bull","year":"2022","journal-title":"BMC Emerg Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41687-022-00435-0","article-title":"Content validation of a new measure of patient-reported barriers to antiretroviral therapy adherence, the I-score: results from a Delphi study","volume":"6","author":"Engler","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"B12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1296894","DOI":"10.3389\/falgy.2023.1296894","article-title":"Addressing the unmet needs in patients with type 2 inflammatory diseases: when quality of life can make a difference","volume":"4","author":"G\u00f3mez de la Fuente","year":"2023","journal-title":"Front Allergy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.4081\/mrm.2022.813","article-title":"Multidisciplinary management of type 2 inflammatory diseases","volume":"17","author":"Senna","year":"2022","journal-title":"Multidiscip Respir Med"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1543504\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T05:13:16Z","timestamp":1743657196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1543504\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":14,"alternative-id":["10.3389\/falgy.2025.1543504"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1543504","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"article-number":"1543504"}}